Search Results for: Clinical Trial Results Marks a
Articles
May 4, 2017
Clinical Trial Results Marks a Significant Accomplishment for Medicortex Finland May 4, 2017
Medicortex Finland Oy (http://www.medicortex.fi) recently announced it completed analyzing the results from the first clinical trial. Medicortex is working toward...
April 2, 2024
Bio-Rad Launches First Ultrasensitive Multiplexed Digital PCR Assay for Breast Cancer Mutation Detection in Clinical Research April 2, 2024
Bio-Rad Laboratories, Inc. recently announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection...
March 26, 2024
Nanoscope Therapeutics Announces Positive Top-line Results From Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa March 26, 2024
Nanoscope Therapeutics Inc. recently announced positive top-line results after the completion of the 2-year Phase 2b RESTORE randomized, controlled clinical trial...
March 22, 2024
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation March 22, 2024
IGC Pharma, Inc. recently announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as...
March 18, 2024
Anavex Life Sciences Initiates Placebo-Controlled US Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia March 18, 2024
Anavex Life Sciences Corp. recently announced the first patient in its US FDA cleared placebo-controlled Phase 2 clinical study of...
March 8, 2024
Athira Pharma Presents Clinical & Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases March 8, 2024
Athira Pharma, Inc. presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD 2024...
February 26, 2024
Tenaya Therapeutics Announces Preclinical HDAC6 Inhibitor Data for Heart Failure With Preserved Ejection Fraction February 26, 2024
Tenaya Therapeutics, Inc. recently announced the publication of preclinical research related to Tenaya’s small molecule inhibitors of histone deacetylase 6...
January 16, 2024
Anavex Life Sciences Announces US Phase 2 Clinical Trial of ANAVEX3-71 in Schizophrenia January 16, 2024
Anavex Life Sciences Corp. recently announced the initiation of the US FDA cleared placebo-controlled Phase 2 trial of ANAVEX3-71 for...
January 3, 2024
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease January 3, 2024
Athira Pharma, Inc. recently announced completion of enrollment in the Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential...
December 20, 2023
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress & Key Milestones Accomplished December 20, 2023
Lipella Pharmaceuticals Inc. recently celebrated its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the company has made substantial strides over the past year, achieving critical milestones….
November 29, 2023
Dyadic Announces Top-Line Results From its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate November 29, 2023
Dyadic International, Inc. recently announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine...
November 21, 2023
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion & Enrollment of First Patient Into Phase 3 Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension November 21, 2023
Aerovate Therapeutics, Inc. recently announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase...
November 15, 2023
SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases November 15, 2023
SciRhom GmbH recently announced the achievement of a significant milestone in its development pipeline. The company has submitted a Clinical...
October 30, 2023
4DMT Gains Alignment With FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy October 30, 2023
4D Molecular Therapeutics recently announced alignment with the US FDA on a plan to lift the clinical hold on the...
August 1, 2023
AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis August 1, 2023
AltruBio Inc. recently announced positive topline data from its Phase 1 trial evaluating the company’s subcutaneously administered immune checkpoint enhancer (ICE),...
June 20, 2023
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV & hMPV in Older Adults June 20, 2023
Icosavax, Inc. recently announced the initiation of a Phase 2 clinical trial of IVX-A12, a combination bivalent respiratory syncytial virus...
June 6, 2023
Anavex Life Sciences Announces Completion of Phase 2/3 Rett Syndrome Clinical Trial June 6, 2023
Anavex Life Sciences Corp. recently announced the completion of dosing of all participants of the placebo-controlled EXCELLENCE Phase 2/3 study...
June 5, 2023
NovelMed Phase 1 Clinical Trial Shows Inhibition of the Alternative Pathway & Preservation of the Classical Pathway – A Long-Acting Anti-Properdin Monoclonal Antibody for PNH Patients June 5, 2023
NovelMed Therapeutics, Inc. recently announced topline results from First-in-Human Phase 1 clinical trial of its complement blocker monoclonal anti-Properdin antibody, known as NM3086…..
February 20, 2023
Kadimastem Submits IND Application for its Phase 2a Clinical Trial With AstroRx for the Treatment of ALS February 20, 2023
Kadimastem Ltd recently has submitted an Investigational New Drug (IND) application to the US FDA for an approval for a multi-site Phase 2a clinical trial to test its lead neurological….
February 13, 2023
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients With Early Alzheimer’s Disease February 13, 2023
Acumen Pharmaceuticals, Inc. recently announced the completion of enrollment in its Phase 1 INTERCEPT-AD trial of ACU193 in patients with early Alzheimer’s disease…..
